Home・Aktien・Syndax Pharmaceuticals Inc
Search

Syndax Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

19.98 3.26

Starkes Kaufsignal

Kursupdate 7. Aug. 2026, 16:31 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.32

Max

20.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

25M

-43M

Verkäufe

-3.6M

65M

EPS

-0.48

Gewinnspanne

-65.788

Angestellte

298

EBITDA

-16M

-31M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+92.02% upside

Dividenden

By Acuity

Nächstes Ergebnis

2. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-147M

1.7B

Vorheriger Eröffnungskurs

16.72

Vorheriger Schlusskurs

19.98

Nachrichtenstimmung

By Acuity

80%

20%

315 / 340 Ranking in Healthcare

Syndax Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Aug. 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, facing volatility amid broader market conditions and recent economic data impacting Federal Reserve policy.

Lesen

5. Aug. 2026, 20:02 UTC

News
Social Media

Syndax Pharmaceuticals shares rise after H.C. Wainwright maintains Buy rating and lowers price target to $38, citing strong revenue growth of $73 million.

Lesen

4. Aug. 2026, 23:11 UTC

News

Syndax Pharmaceuticals shares are lower in after-market hours following a second-quarter earnings miss, reporting a net loss of $49.4 million and revenue of $72.8 million.

Lesen

3. Aug. 2026, 19:16 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares are higher amid a broader market rally. The stock remains below its 20-day moving average and near the lower end of its one-month range.

Lesen

31. Juli 2026, 20:06 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares declined after first-quarter results showed lower performance. Broader market pressures from rising yields and oil prices contributed to the decline.

Lesen

30. Juli 2026, 17:06 UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

Lesen

29. Juli 2026, 19:56 UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

Lesen

28. Juli 2026, 20:51 UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

Lesen

27. Juli 2026, 20:06 UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

Lesen

24. Juli 2026, 19:52 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

Lesen

22. Juli 2026, 19:06 UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Lesen

Peer-Vergleich

Kursveränderung

Syndax Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

92.02% Vorteil

12-Monats-Prognose

Durchschnitt 38.25 USD  92.02%

Hoch 57 USD

Tief 26 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Syndax Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

9

Buy

0

Halten

0

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Syndax Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

315 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Andere Aktien aus dem Sektor

JNJ

Johnson and Johnson

257.05

↓-0.22%

ABBV

AbbVie Inc

243.68

↓-0.99%

UNH

UnitedHealth Group Inc

403.72

↓-2.25%

NVS

Novartis AG

154.08

↓-0.05%

AZN

AstraZeneca PLC

160.97

↓-0.25%
help-icon Live chat